Companies believe that the C5 aptamer blockade represents a potential breakthrough therapy.

Ophthotech and Archemix inked an agreement for the treatment of the wet and dry forms of age-related macular degeneration (AMD).

Under this exclusive, worldwide license deal, Ophthotech gains worldwide rights to all ophthalmic uses of Archemix’ aptamers targeting the C5 component of the complement cascade.

“Preclinical and human genetic linkage studies have demonstrated the significant role of complement mediated inflammation in both forms of AMD,” notes Samir Patel, M.D., president and CEO of Ophthotech. “We believe that the anti-C5 aptamer blockade represents a potential breakthrough therapy for dry and wet AMD.”

Previous articlebioMérieux Contracts Sloning to Provide Gene Mutant Library for Use in Diagnostics Program
Next articleDiverse Genetic Abnormalities Implicated in NF-kB Activation in Multiple Myeloma